Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Vraag dan direct offertes aan
EllingsgaardHHauselmannISchulerBHabibAMBaggioLLMeierDTet al
Other Health Benefits Retatrutide also helps with other health issues
Int.J Cardiol
Future: Dedicated NASH Phase 3 Trial Expected Timeline IF Retatrutide Approved for Obesity/Diabetes (2028): 2027-2028: Dedicated NASH Phase 3 trial begins Population: Biopsy-confirmed NASH with fibrosis (F1-F3) Primary endpoint: NASH resolution without worsening fibrosis Baseline and Week 72-96 liver biopsies Duration: 18-24 months minimum 2029-2030: Trial results published 2030-2031: FDA approval decision for NASH indication Why This Matters Current Reality: Only one FDA-approved medication exists for NASH resmetirom (Rezdiffra), approved March 2024
US$ 28.38
US$ 26.52
US$ 23.53
US$ 26.67
US$ 24.16
US$ 26.46
